Quantcast
Last updated on April 19, 2014 at 8:45 EDT

Latest Enanta Pharmaceuticals Inc. Stories

2013-11-29 08:23:36

NEW YORK, November 29, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Echo Therapeutics, Inc. (NASDAQ: ECTE), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Cyberonics Inc. (NASDAQ: CYBX), and Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). Today's readers may access these reports free of charge - including full...

2012-11-06 16:29:03

WATERTOWN, Mass., Nov. 6, 2012 /PRNewswire/ -- Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. Enanta previously submitted its registration statement to the SEC on a confidential basis under the...

2012-10-17 11:24:01

WATERTOWN, Mass., Oct. 17, 2012 /PRNewswire/ -- Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced that Abbott initiated an interferon-free combination Phase 3 clinical trial for hepatitis C (HCV) that included the collaboration's protease inhibitor, ABT-450. This trial was initiated following the release of positive results from the study known as "Aviator", a...

2012-09-19 02:30:20

WATERTOWN, Mass., Sept. 19, 2012 /PRNewswire/ -- Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that Enanta was named by FierceBiotech as one of 2012's Fierce 15. The annual award, which was announced today during the BioPharm America Conference at the Westin Boston Waterfront Hotel in Boston, was created by FierceBiotech to recognize 15 promising private...

2012-04-04 06:27:17

WATERTOWN, Mass., April. 4, 2012 /PRNewswire/ --Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating best-in-class small molecule drugs in the infectious disease field, announced today that key data from two of its hepatitis C (HCV) programs will be presented at the International Liver Congress(TM) 2012 (ILC2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain. Oral...

2012-02-21 06:01:00

WATERTOWN, Mass., Feb. 21, 2012 /PRNewswire/ -- Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating best-in-class small molecule drugs in the infectious disease field, announced today that it has entered into an exclusive collaboration and license agreement with Novartis for the worldwide development, manufacture and commercialization of its lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. Enanta has received IND...

2011-10-13 07:00:00

WATERTOWN, Mass., Oct. 13, 2011 /PRNewswire/ -- Enanta Pharmaceuticals, Inc., a clinical stage infectious disease biopharmaceutical company, announced today the award of a contract from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), worth up to $42.7 million over five years. The award will fund the preclinical and clinical development of a new class of bridged bicyclic antibiotics known as Bicyclolides to be used...

2011-09-26 08:02:00

WATERTOWN, Mass., Sept. 26, 2011 /PRNewswire/ -- Enanta Pharmaceuticals, Inc. announced today that its lead development candidate from its NS5A hepatitis C virus (HCV) inhibitor program, EDP-239, has been recognized on Windhover's list of the "Top 10 Most Interesting Infectious Disease Projects to Watch." EDP-239 was chosen by independent experts at Windhover Information and Herndon Company. NS5A, a clinically-validated target, is a non-structural viral protein that is essential to viral...

2010-03-02 08:30:00

WATERTOWN, Mass., March 2 /PRNewswire/ -- Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day dosing. "Our NS5A inhibitor program is well positioned to generate a pipeline of clinical candidates, and we are excited about further...